HC Wainwright Has Strong Forecast for VERA FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Vera Therapeutics to a loss of $5.94 per share from a projected loss of $6.52, while maintaining a Buy rating and $75 price target.
• Vera reported a quarterly loss of $1.30 per share, better than analysts’ $1.62 loss estimate, and revenue of $10.28 million versus the $3.42 million forecast.
• Analyst sentiment is generally positive: MarketBeat’s consensus is “Moderate Buy,” with an average price target of $74.93, though ratings include two Holds and one Sell.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Vera Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst A. He now expects that the company will earn ($5.94) per share for the year, up from their previous estimate of ($6.52). HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($6.45) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q4 2026 earnings at ($1.43) EPS, Q1 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.61) EPS and FY2027 earnings at ($4.24) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.30) EPS for the quarter, beating analysts' consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million.

A number of other analysts also recently commented on VERA. Weiss Ratings reissued a "sell (d-)" rating on shares of Vera Therapeutics in a report on Thursday, October 15th. TD Cowen restated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Leerink Partners initiated coverage on shares of Vera Therapeutics in a report on Monday, October 12th. They issued a "market perform" rating and a $34.00 target price for the company. Guggenheim reduced their price target on shares of Vera Therapeutics from $76.00 to $66.00 and set a "buy" rating for the company in a research report on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $74.93.

Vera Therapeutics Stock Performance

Shares of VERA opened at $30.61 on Tuesday. The company has a 50-day simple moving average of $31.53 and a 200-day simple moving average of $36.60. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.21 billion, a PE ratio of -5.19 and a beta of 1.07. Vera Therapeutics has a 52-week low of $26.00 and a 52-week high of $56.05.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,704,028. This represents a 7.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company's stock.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP raised its stake in shares of Vera Therapeutics by 66.3% in the 3rd quarter. Allworth Financial LP now owns 1,515 shares of the company's stock valued at $49,000 after purchasing an additional 604 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Vera Therapeutics by 9.6% during the third quarter. Russell Investments Group Ltd. now owns 54,532 shares of the company's stock worth $1,761,000 after purchasing an additional 4,797 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Vera Therapeutics in the third quarter worth about $32,000. Fifth Third Bancorp grew its stake in Vera Therapeutics by 49.8% in the third quarter. Fifth Third Bancorp now owns 165,245 shares of the company's stock worth $5,336,000 after purchasing an additional 54,942 shares in the last quarter. Finally, Fulcrum Asset Management LLP acquired a new position in Vera Therapeutics in the third quarter worth about $74,000. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs.

Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.